BackGlaukos Overview
Glaukos Corporation

Glaukos Target Price

Where could GKOS trade next? Consensus target price: $180.

Get informed when a big investor buys or sells

+ Follow

Share Price

$177.47

Average Target Price

$180.771.9% upside

13 analysts in the last 4 months

High: $215 | Low: $150

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-20BTIG$20213.8% upsideOpen
2026-07-30H.C. Wainwright$1959.9% upsideOpen
2026-07-30Stifel Nicolaus$1907.1% upsideOpen
2026-07-30Piper SandlerMatt O'Brien$1959.9% upsideOpen
2026-07-30Wells FargoLarry Biegelsen$1780.3% upsideOpen
2026-07-30NeedhamDavid Saxon$20113.3% upsideOpen
2026-07-30Truist FinancialRichard Newitter$21521.1% upsideOpen
2026-07-28UBS$15015.5% downsideOpen
2026-07-16Truist Financial$1801.4% upsideOpen
2026-07-13BTIG$1647.6% downsideOpen
2026-07-06H.C. Wainwright$1685.3% downsideOpen
2026-06-17NeedhamDavid Saxon$15015.5% downsideOpen
2026-05-21BTIGRyan Zimmerman$1628.7% downsideOpen
2026-04-30Stifel NicolausThomas Stephan$1704.2% downsideOpen
2026-04-30BTIG$14120.5% downsideOpen
2026-04-30Needham$13623.4% downsideOpen
2026-02-18NeedhamDavid Saxon$12728.4% downsideOpen
2026-02-18Wells Fargo$13523.9% downsideOpen
2026-01-28BTIG$13126.2% downsideOpen
2026-01-22Stifel Nicolaus$1609.8% downsideOpen
2026-01-14Piper Sandler$1657% downsideOpen
2026-01-09Goldman Sachs$13822.2% downsideOpen
2026-01-02Stephens$14518.3% downsideOpen
2025-12-23UBS$14518.3% downsideOpen
2025-12-18Truist Financial$14518.3% downsideOpen
2025-12-17UBS$1657% downsideOpen
2025-12-17Piper Sandler$6165.6% downsideOpen
2025-12-09Needham$12529.6% downsideOpen
2025-11-10UBSDanielle Antalffy$14021.1% downsideOpen
2025-10-30Truist FinancialRichard Newitter$12032.4% downsideOpen
2025-10-30BTIG$11634.6% downsideOpen
2025-10-30Wells Fargo$12231.3% downsideOpen
2025-10-30NeedhamDavid Saxon$11734.1% downsideOpen
2025-10-27Stifel NicolausThomas Stephan$11535.2% downsideOpen
2025-10-13BTIGRyan Zimmerman$10441.4% downsideOpen
2025-10-01Goldman Sachs$10342% downsideOpen
2025-07-31Mizuho Securities$13026.7% downsideOpen
2025-05-01Truist FinancialRichard Newitter$13523.9% downsideOpen
2024-12-31Stifel NicolausThomas Stephan$1751.4% downsideOpen
2024-12-18Truist FinancialRichard Newitter$1854.2% upsideOpen
2024-12-02Stifel NicolausThomas Stephan$15313.8% downsideOpen
2024-12-02Morgan StanleyPatrick Wood$12032.4% downsideOpen
2024-11-05NeedhamDavid Saxon$14916% downsideOpen
2024-11-05BTIGRyan Zimmerman$14021.1% downsideOpen
2024-10-29JefferiesMichael Sarcone$15512.7% downsideOpen
2024-10-21Truist FinancialSamuel Brodovsky$15214.4% downsideOpen
2024-10-17Piper SandlerMatt O'Brien$14021.1% downsideOpen
2024-09-23BTIGRyan Zimmerman$13921.7% downsideOpen
2024-09-03Stifel NicolausThomas Stephan$14518.3% downsideOpen
2024-06-05Stifel NicolausThomas Stephan$13026.7% downsideOpen

Glaukos (GKOS) FAQ

As of the most recent data, GKOS shows a target price of $180. Scroll down for historical charts and peer comparison views.

If Glaukos moved to the average analyst target of $180, shares would be roughly 1.9% higher than $177.47. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Glaukos's earnings trajectory.

Besides this target price page, Stockcircle has Glaukos's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $180) with ownership activity and broader fundamentals.

Glaukos's target price is $180; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.